scispace - formally typeset
Journal ArticleDOI

The interferon signature in autoimmune diseases.

Lars Rönnblom, +1 more
- 01 Mar 2013 - 
- Vol. 25, Iss: 2, pp 248-253
Reads0
Chats0
TLDR
The observed IFN signature in several autoimmune diseases is a biomarker of active disease and is investigated as a tool when selecting treatment for individual patients.
Abstract
Purpose of reviewAn increased expression of type I interferon (IFN) regulated genes (an IFN signature) has been reported in blood and tissue cells from patients with SLE and other autoimmune diseases. We review the possible mechanisms behind the IFN signature as well as clinical and therapeutic cons

read more

Citations
More filters
Journal ArticleDOI

Coordination between innate immune cells, type I IFNs and IRF5 drives SLE pathogenesis.

TL;DR: Elevated IFNα activity was detected in the sera of SLE patients carrying IRF5 risk polymorphisms who were positive for either anti-RNA binding protein ( anti-RBP) or anti-double-stranded DNA (anti-dsDNA) autoantibodies.
Journal ArticleDOI

Type I interferon gene signature test–low and –high patients with systemic lupus erythematosus have distinct gene expression signatures:

TL;DR: These results provide new insights into the molecular heterogeneity underlying SLE pathogenesis, highlighting shared mechanisms beyond type I IFN, across several autoimmune diseases.
Journal ArticleDOI

IFNλ Stimulates MxA Production in Human Dermal Fibroblasts via a MAPK-Dependent STAT1-Independent Mechanism.

TL;DR: Findings reveal cutaneous cell type-specific IFN signaling and suggest that IFNλ, although important for epidermal antiviral competence, may also have a regulatory role in the dermal compartment balancing type I IFN-induced inhibition of tissue repair processes.
Journal ArticleDOI

Immunotherapeutic Biologic Agents in Autoimmune and Autoinflammatory Diseases.

TL;DR: In this review, key immunotherapeutic approaches for treating inflammatory autoimmune disorders, such as rheumatoid arthritis and systemic lupus erythematosus (SLE), as well as genetic autoinflammatory diseases,such as cryopyrin associated periodic syndromes, are addressed.
Journal ArticleDOI

Targeting IFN-λ: therapeutic implications.

TL;DR: Type-III interferons (IFN-λ), the most recently discovered family of IFNs, shares common features with other family members, but also has many distinctive activities, including anti-tumor, immune-inflammatory and homeostatic functions.
References
More filters
Journal ArticleDOI

Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus

TL;DR: Global gene expression profiling of peripheral blood mononuclear cells is used to identify distinct patterns of gene expression that distinguish most SLE patients from healthy controls, and identify a subgroup of patients who may benefit from therapies targeting the IFN pathway.
Journal ArticleDOI

Interferon and Granulopoiesis Signatures in Systemic Lupus Erythematosus Blood

TL;DR: Microarray analysis of blood cells reveals that immature granulocytes may be involved in SLE pathogenesis, and the IFN signature confirms the central role of this cytokine in Sle, using oligonucleotide microarrays.
Journal ArticleDOI

JAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated Disease

TL;DR: Not only have genome-wide association studies demonstrated that this pathway is highly relevant to human autoimmunity, but targeting JAKs is now a reality in immune-mediated disease.
Related Papers (5)